GSK Loses Bid To End 53 Zofran Birth Defects Cases
GlaxoSmithKline has largely lost its bid to end 58 cases in a consolidated suit claiming its anti-nausea medication Zofran caused birth defects when taken by pregnant women, as a Massachusetts federal judge...To view the full article, register now.
Already a subscriber? Click here to view full article